

The Word on the Covid-19 Vaccine: What We Know So Far

TBT buttonwoodtree.net/index.php/2020/12/23/the-word-on-the-covid-19-vaccine-what-we-know-so-far/

December 23, 2020

By

Diana Rangaves, PharmD

December 23, 2020



It would be an understatement to say that 2020 was a difficult year for everyone without a vaccine. Most of the world has been living in perpetual fear for several months. This includes the economic downturn various industries have faced including agriculture, energy, tourism, and retail businesses.

READ MORE: COVID-19 Causes Stress on U.S. Agriculture

Still, scientists and researchers have worked tirelessly. Therefore, the search for a vaccine against the novel coronavirus has seen some fruit.

The news these days certainly seems hopeful. However, the information is still conflicting. It might be helpful to take a brief look at what we know about the Covid-19 vaccine and its progress so far. This information might give many people a ray of hope and the motivation to carry on for ...

[Login In](#)

or

[Register now for free access](#)

[Forgot Password](#)


Notify of

Inline Feedbacks

View all comments




Most Popular



[The 2021 Private Equity Predictions from PitchBook](#)

[Articles](#) [Anna Betchel](#)


As the year comes to a close, PitchBook has begun to make predictions for the new year. Here are their 2021 private equity predictions.



[Distressed Asset Monthly Report: June](#)

Bankruptcy Joseph Weitemeyer


The amount of casualties left in the wake of COVID-19 continues to tally. Seven additional private equity-owned companies defaulted in June, six...



SoftBank Affiliated Blank-Check Company SVF Investment Corp. 3 Announces IPO Looking at AI and...

Investment Banking Jonathon Meyers

SVF Investment Corp. 3 has filed paperwork with the SEC registering 40 million units of securities to trade on the NASDAQ. Each...



Challenges in Life Sciences: What 2020 Meant for This Industry

Articles Diana Rangaves, PharmD

When we compare life sciences and healthcare to other industries, the strategy in the former is much more fragmented. The pricing practices are also relatively unbalanced while the product cycle is quite long as well.

